REGN earnings call for the period ending June 30, 2019.
News & Analysis: Regeneron Pharmaceuticals
Revenue and earnings beat Wall Street estimates thanks to solid growth for Eylea and Dupixent.
It can be tough to pick winners in the world of pharmaceutical development, but Alexion, Regeneron, and Ionis offer investors good chances of strong returns.
Here's how these biotech stocks became the biggest on the market -- and how their future prospects look.
Sales growth is slowing, and there's an issue with one of the biotech's pipeline drugs.
This big-cap biotech has a problem or two on its hands.
REGN earnings call for the period ending March 31, 2019.
The big biotech disappointed investors in the first quarter with slower-than-expected revenue and earnings growth. Here's what you need to know.
Which stock wins in a battle between these two successful biotechs?
These drugmakers' profit margins are sky-high. But does that necessarily mean they're great stocks to buy?